[go: up one dir, main page]

PE20081687A1 - Proteina de fusion - Google Patents

Proteina de fusion

Info

Publication number
PE20081687A1
PE20081687A1 PE2008000128A PE2008000128A PE20081687A1 PE 20081687 A1 PE20081687 A1 PE 20081687A1 PE 2008000128 A PE2008000128 A PE 2008000128A PE 2008000128 A PE2008000128 A PE 2008000128A PE 20081687 A1 PE20081687 A1 PE 20081687A1
Authority
PE
Peru
Prior art keywords
joined
fusion protein
same
fragment
epitops
Prior art date
Application number
PE2008000128A
Other languages
English (en)
Inventor
Normand Blais
Martine Boyer
Vincent Brichard
Jamila Louahed
Denis Martin
Remi M Palmantier
Clement Rioux
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700759A external-priority patent/GB0700759D0/en
Priority claimed from GB0709707A external-priority patent/GB0709707D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20081687A1 publication Critical patent/PE20081687A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UN ANTICUERPO HUMANIZADO O PROTEINA DE FUSION, LA CUAL COMPRENDE: A) NY-ESO-1 O UN FRAGMENTO QUE INCLUYA UNO O MAS EPITOPOS DEL MISMO Y SU EXTREMO C SE UNA A LAGE-1; B) LAGE-1 O UN FRAGMENTO QUE INCLUYA UNO O MAS EPITOPOS DEL MISMO Y SU EXTREMO N SE UNE A NY-ESO-1; C) UN COMPONENTE DE FUSION HETEROLOGO, TAL COMO LA PROTEINA D O UN FRAGMENTO REPRESENTADO POR LOS AMINOACIDOS 20 A 127 DE LA MISMA, CUYA PORCION N SE UNE CON LOS AMINOACIDOS Met, Asp Y Pro; D) UNA MARCA DE AFINIDAD, TAL COMO HISTIDINA. TAMBIEN SE REFIERE AL AMINOACIDO CODIFICADOR, VECTOR, CELULA HUESPED, PROCEDIMIENTO DE PREPARACION Y ADICIONALMENTE UN ADYUVANTE O QUIMIOCINA PARA DAR UNA COMPOSICION INMUNOGENICA. DICHA PROTEINA DE FUSION INDUCE RESPUESTA INMUNE CONTRA CELULAS CANCERIGENAS
PE2008000128A 2007-01-15 2008-01-11 Proteina de fusion PE20081687A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0700759A GB0700759D0 (en) 2007-01-15 2007-01-15 Novel fusion protein
US91484807P 2007-04-30 2007-04-30
US91492507P 2007-04-30 2007-04-30
GB0709707A GB0709707D0 (en) 2007-05-21 2007-05-21 Novel fusion protein

Publications (1)

Publication Number Publication Date
PE20081687A1 true PE20081687A1 (es) 2008-12-25

Family

ID=41111108

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000128A PE20081687A1 (es) 2007-01-15 2008-01-11 Proteina de fusion

Country Status (15)

Country Link
EP (1) EP2118128B1 (es)
JP (1) JP2010532656A (es)
KR (1) KR20090122426A (es)
BR (1) BRPI0806501A2 (es)
CA (1) CA2674458A1 (es)
DK (1) DK2118128T3 (es)
EA (1) EA016818B1 (es)
ES (1) ES2398492T3 (es)
HR (1) HRP20130022T1 (es)
MX (1) MX2009007572A (es)
PE (1) PE20081687A1 (es)
PL (1) PL2118128T3 (es)
SI (1) SI2118128T1 (es)
TW (1) TW200902049A (es)
WO (1) WO2008089074A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008308474A (ja) * 2007-06-18 2008-12-25 Nitto Denko Corp 抗原ペプチド製剤の調製方法
CA2755734A1 (en) * 2009-03-17 2010-09-23 Gaetan Otto Improved detection of gene expression
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
CA2847332A1 (en) * 2011-08-31 2013-03-07 Mie University Vaccine preparation for cancer treatment
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2014207708A2 (en) * 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
EP3053592B1 (en) 2013-10-01 2025-04-23 Mie University T cell-inducing vaccine containing interepitope sequence promoting antigen presentation
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
CA3119865A1 (en) * 2018-11-23 2020-05-28 Strike Pharma Ab Bi-specific conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06205672A (ja) * 1992-03-19 1994-07-26 Nippon Zeon Co Ltd 日本脳炎ウイルス及びｂ型肝炎ウイルスの表面抗原タンパク質の抗原部位を持つキメラタンパク質の製造法、およびそれに用いる組み換えバキュロウイルス
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
ES2362715T3 (es) * 2000-03-30 2011-07-12 Dendreon Corporation Composiciones y métodos para inmunoterapia a base de células dendríticas.
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
MXPA06007144A (es) * 2003-12-24 2007-01-31 Cerus Corp Moleculas de acido nucleico recombinante que codifican proteinas de fusion que comprenden polipeptidos de senal secretoria bacterial y de antigenos, casetes de expresion y bacterias, y metodos para usar las mismas.
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
WO2006053871A2 (en) * 2004-11-16 2006-05-26 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
US20090186049A1 (en) * 2006-05-26 2009-07-23 Vincent Brichard Method of treating mage positive cancer
PL2114993T3 (pl) * 2007-01-15 2013-01-31 Glaxosmithkline Biologicals Sa Szczepionka

Also Published As

Publication number Publication date
ES2398492T3 (es) 2013-03-19
TW200902049A (en) 2009-01-16
JP2010532656A (ja) 2010-10-14
KR20090122426A (ko) 2009-11-30
WO2008089074A2 (en) 2008-07-24
PL2118128T3 (pl) 2013-03-29
EP2118128B1 (en) 2012-11-07
WO2008089074A9 (en) 2012-07-12
WO2008089074A3 (en) 2008-12-31
BRPI0806501A2 (pt) 2014-04-22
HRP20130022T1 (hr) 2013-02-28
EP2118128A2 (en) 2009-11-18
EA200900738A1 (ru) 2010-02-26
EA016818B1 (ru) 2012-07-30
DK2118128T3 (da) 2013-02-18
SI2118128T1 (sl) 2013-02-28
CA2674458A1 (en) 2008-07-24
MX2009007572A (es) 2009-10-13

Similar Documents

Publication Publication Date Title
PE20081687A1 (es) Proteina de fusion
MX2020004578A (es) Composiciones de casz y metodos de uso.
AR078423A1 (es) Vacunas dirigidas a las celulas de langerhans
MX2018011836A (es) Conjugados de anticuerpo farmaco anti-cd70.
CO6382140A2 (es) Composiciones de vacuna que comprenden una proteina de enlace del factor h mutada
BR112013027829A2 (pt) anticorpos anti-cd40 e método de uso
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
CR20200408A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027).
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
BR112015017548A8 (pt) construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit
CR20150625A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
BRPI0708344A8 (pt) Vetores adenovirais quiméricos e composição imunogênica
GT201200271A (es) Proteínas que se unen al tnf-a
AR078778A1 (es) Proteinas de union a antigenos de il-23
CR20160570A (es) Anticuerpos anti-pld1 y su uso para mejorar la función de las celulas t
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
AR101669A1 (es) Constructos de anticuerpos para cdh19 y cd3
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
AR091649A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CL2012001966A1 (es) Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis.
CO6351750A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf

Legal Events

Date Code Title Description
FA Abandonment or withdrawal